Researchers at Penn Medicine and University of Leeds, co-led by the Basser's Roger Greenberg, MD, PhD, have deciphered the structure of a multipart, molecular complex that is also responsible for regulating the immune system and have found new molecular targets for fighting autoimmunity.

The Philadelphia Inquirer highlights a Penn Medicine and Basser Center study, led by Kim Reiss Binder, MD, an assistant professor of Hematology-Oncology, which examines PARP inhibitors in patients with BRCA mutations.

Basser Center genetic counselor Dana Farengo Clark, MS, LCGC, helps to explain BRCA mutations and the process of genetic testing and counseling.

Basser Center Executive Director Susan Domchek, MD, discusses the role of specific PARP inhibitors in an ongoing breast cancer trial.

Basser Center founders Mindy and Jon Gray have a well-deserved spot on Forbes' annual list of top 50 philanthropists. "In total, Gray has given over $120 million in his lifetime, primarily to cancer research and health and education in New York City."

Basser’s Susan Domchek, MD, and Penn Medicine patient Steven Merlin, whose participation in groundbreaking clinical trials using PARP inhibitor drugs has kept him cancer-free for six years, comment on how BRCA mutations affect men.

Using CRISPR, a team assessed 3,893 otherwise unstudied mutations of BRCA1, which normally suppresses cancerous tumors, but can be rendered ineffective when they’re mutated. 

The Basser family patriarch, Phil Basser, father to the Center's co-founder Mindy Gray and Basser Global Prize co-founder Shari Potter, is featured in the Jewish Exponent for his century of loving Philadelphia football.

WHYY's The Pulse sat down with Dana Clark, MS, LCGC, a genetic counselor in the Basser Center, to learn how these services are affecting decisions and outlooks on health.

The San Diego Union-Tribune reports on our upcoming panel on hereditary cancer and BRCA in La Jolla, California.